Marrow transplantation following busulfan and cyclophosphamide in multiple myeloma.
We report the use of busulfan and cyclophosphamide as conditioning before allogeneic bone marrow transplantation for a 38-year-old man with multiple myeloma. Three months post-transplant the monoclonal IgA band previously present was no longer detectable in the serum and plasma cells were no longer visible in the marrow. The patient died on day 93 with fungal infection. We conclude that the combination of busulfan and cyclophosphamide could be valuable before transplant for other patients with multiple myeloma.
D000328:Adult; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy / Q000601:surgery*; D011300:Preoperative Care / Q000379:methods; D012074:Remission Induction
D003520:Cyclophosphamide; D002066:Busulfan